Loading
Life sciences · Journal article
Clinical Obesity · September 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual agonists have become pivotal options for obesity, but marked weight loss heterogeneity remains poorly understood. This meta‐regression analysis aimed to identify factors influencing this heterogeneity. We searched Medline, Embase, The Cochrane Library, and Web of Science up to February 1, 2026, enrolling 32 eligible trials (40 408 participants) following PRISMA guidelines. Meta‐regression and subgroup analyses were performed using R software. Pooled analysis showed that GLP‐1RAs and dual agonists achieved a weighted mean weight reduction of 9.36% (95% CI 7.92%–10.80%), with high interstudy heterogeneity ( I 2 = 99.6%, p < 0.001). Subgroup analyses revealed that GLP‐1/GIP dual agonists (tirzepatide) and longer treatment duration (≥ 72 weeks) yielded superior weight‐lowering effects. Meta‐regression demonstrated that baseline anxiety/depression was positively associated with weight loss efficacy ( β = 2.44, p < 0.001, R 2 = 81.34%). Comorbid Type 2 diabetes mellitus (T2DM), obstructive sleep apnea (OSA) and metabolic dysfunction‐associated fatty liver disease (MAFLD) were negatively correlated with treatment response (all p < 0.05). Emotional state and metabolic comorbidities including T2DM, OSA and MAFLD are important influencing factors of the interindividual differences of weight loss efficacy of GLP‐1RAs and dual agonists, providing evidence for personalized obesity management.